Cell-free DNA (cfDNA) is significantly utilized for the fetal DNA screening tests to monitor the chromosomal abnormalities, as a biomarker for the particular mutations detection in the cancer victims, as a biomarker to detect post transplantation rejection, and several other applications. Whereas, these are non-encapsulated fragments of DNA molecule exists in the blood and urine that has the broad screening and diagnostics applications. According to the Center of Disease Control and Prevention, approximately 6,000 babies are born with the Down disorder every year that is around 1 in every 700 babies and the syndrome incidence is augmented by approximately 30% among 1979 and 2003. In addition, according to the analysis by the World Health Organization, nearly 14 million fresh cancer cases were diagnosed and are anticipated to increase by approximately 70% over the coming 2 decades.
Not only has this, the market of cell-free DNA is boosting owing to the developed maternal age, growing number of chronic syndrome, transformation in the lifestyle that leads to the lifestyle syndrome such as cancer, and the unhealthy food habits. The effective rise in the disease incidence along with the growing medical spending and healthcare expense deliver the opportunities for the molecular diagnostics corporates to come up along the effective number of advancements and innovations tests in the market. Whereas, there is a wide market place for the molecular diagnostic corporates to enter along the novel tests directing on the transplantation rejection cases like lung, liver and several others in the coming years.
According to the report analysis, ‘Cell-free DNA Testing Market – Global Drivers, Restraints, Opportunities, Trends, and Forecasts: 2017-2023’ states that there are several key players which recently performing in the Cell-free DNA market more actively for leading the fastest market growth and dominating the high value of revenue across the globe throughout the short span of time while significant leading the healthcare expenditure and increasing healthcare consciousness in the underdeveloped regions and augmenting the strategies of mergers and acquisitions includes Natera, Inc., Beijing Genomics Institute, F. Hoffmann-La Roche (Roche), Laboratory Corporation of America Holdings, Illumina, Inc., Guardant Health, Trovagene, Inc., Biocept, Inc., and several other predominate & niche players.
The Global Cell-free DNA Testing Market is predicted to observe an efficient CAGR of 26.5% during the forecast period of 2017-2023.However, the market of Cell-free DNA is spread across the globe which extremely involves North America, Europe, Asia Pacific, and Rest of the World (RoW). The Americas is set to be the foremost region for the cfDNA testing market growth followed by Europe. Asia Pacific and RoW are set to be the underdeveloped economies.
In the recent times, the cfDNA tests register the cfDNA testing market across the globe. A lot of new players are aiming on this market to deliver the innovative tests with great accurateness and less turnaround time. Many foremost players in the market are establishing new products to manage their governance in the market. Apart from this, the big players are attaining the small companies in the market to develop their product portfolio and manage their market leadership. For instance, in September 2016, LabCorp assimilated Sequenom to toughen its non-invasive prenatal testing product portfolio. Therefore, in the near years, it is anticipated that the market of Cell-free DNA testing will increase around the globe more positively over the coming years.
For more information on the research report, refer to below link:-
Global Cell Free DNA Testing Market
Contact Us:-
Ken Research
Ankur Gupta, Head Marketing & Communications
Sales@kenresearch.com
+91-9015378249
